E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
- primary myelofibrosis (PMF), - post-polycythemia vera myelofibrosis (post-PV MF), or - post-essential thrombocythemia myelofibrosis (post-ET MF). |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10028537 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the objective response rate (ORR) of plitidepsin according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT, Appendix 1) in patients with: - primary myelofibrosis (PMF), - post-polycythemia vera myelofibrosis (post-PV MF), or - post-essential thrombocythemia myelofibrosis (post-ET MF). |
|
E.2.2 | Secondary objectives of the trial |
1- To evaluate the safety and tolerability of plitidepsin in this study population. 2- To determine the effect of plitidepsin on: - bone marrow (BM) or peripheral blood histologic and cytogenetic findings, and - peripheral blood granulocyte JAK2V617F allele burden. 3- To determine the quality of life (QoL) and symptoms assessment according to the Myelofibrosis Symptom Assessment Form (MFSAF) (Appendix 2), after treatment with plitidepsin. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Diagnosis of PMF or post-ET/PV MF as per revised World Health Organization (WHO) criteria (Appendix 3). 2)High-risk or intermediate-2 risk MF as defined by the International Prognostic Scoring System (IPSS) (Appendix 4); or intermediate-I risk MF associated with symptomatic splenomegaly/hepatomegaly and/or unresponsive to available therapy. 3)At least 18 years of age, with life expectancy of >/=12 weeks. 4)Able to provide informed consent and being willing to sign an informed consent form (ICF). 5)Eastern Cooperative Oncology Group (ECOG) performance status </=2 (Appendix 5). 6)Evidence of acceptable organ function within seven days of initiating study drug, as evidenced by the following: a)Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) </= 3.0 x upper limit of normal (ULN). b)Direct bilirubin </= 1.0 x ULN. c)Absolute neutrophil count (ANC) >/= 1.0 x 10^9/L. d)Platelet count >/= 25 x 10^9/L. e)Left ventricular ejection fraction (LVEF) within normal limits. f)Creatine phosphokinase (CPK) </= 2.5 x ULN. g)Creatinine clearance >/= 40 mL/min. |
|
E.4 | Principal exclusion criteria |
1.Previous treatment with plitidepsin. 2.Any of the following therapies within two weeks prior to initiation of study drug: a)chemotherapy (e.g., hydroxyurea), b)immunomodulatory drug therapy (e.g., thalidomide), c)immunosuppressive therapy, d)corticosteroids >10 mg/day prednisone or equivalent, or e)erythropoietin. 3.Incomplete recovery from major surgery within four weeks of study entry. 4.Radiation therapy within four weeks of study entry. 5.Women of childbearing potential, unless surgically sterile for at least three months (i.e., hysterectomy), or postmenopausal for at least 12 months (follicle-stimulating hormone, FSH > 30 U/mL), or unless they agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) throughout the treatment period and for six months after discontinuation of the treatment. Permitted methods for preventing pregnancy must be communicated to the study patients and their understanding has to be confirmed. 6. Men who partner with a woman of childbearing potential, unless they agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) throughout the treatment period and for six months after discontinuation of the treatment. Permitted methods for preventing pregnancy must be communicated to the study subjects and their understanding has to be confirmed. 7.Women who are pregnant or are currently breastfeeding. 8.Myopathy grade > 2 or any clinical situation that causes significant and persistent elevation of CPK (> 2.5 x ULN in two different determinations performed one week apart). 9.Known positive status for human immunodeficiency virus (HIV). 10.Active hepatitis B or C virus (HBV or HCV) infection and/or significant non-neoplastic liver disease (i.e. cirrhosis). 11.Diagnosis of another invasive malignancy unless free of disease for at least three years following therapy with curative intent. Patients with early-stage basal cell or squamous cell skin cancer, cervical intraepithelial neoplasia, cervical carcinoma in situ, or superficial bladder cancer, may be eligible to participate at the Investigator`s discretion. 12.Any acute active infection. 13.Serious concomitant systemic disorders that would compromise the safety of the patient or limit the patient’s ability to complete or comply with the study, including: a)Uncontrolled medical illness that the Investigator feels will compromise the patient’s tolerance to the study medication. b)Uncontrolled or unstable angina, myocardial infarction, cerebrovascular accident, valvular heart disease or congestive heart failure (New York Heart Association Classification 3 or 4), within 12 months prior to initiation of study drug. c)Pulmonary embolism within three months prior to initiation of study drug. d)Uncontrolled arterial hypertension (>/= 160/110 mmHg) despite optimal medical therapy. e)Previous treatment with doxorubicin at cumulative doses >/= 450 mg/m2. f)Symptomatic arrhythmia (excluding anemia-related sinusal tachycardia grade </= 2), or prolongation of the QTc (Bazzett`s, QTcB) interval to >450 msec for men or >470 msec for women at pre-study screening, unless attributable to pre-existing bundle branch block. 14.Known hypersensitivity to the study drug or any of its formulation components (e.g., Cremophor). 15.Treatment with any investigational product in the 30 days before inclusion in the study. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of this trial is the treatment success rate, with success defined as confirmed disease response. A confirmed response is deemed to be an objective status of complete response (CR), partial response (PR), or clinical improvement (CI), according to the IWG-MRT consensus criteria (i.e., on two consecutive evaluations performed at least eight weeks apart). |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
La conclusione dello studio e` prevista 4 settimane dopo l`interruzione del trattamento dell`ultimo paziente in trattamento |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |